He will be replaced as head of AbbVie’s global R&D organisation by Roopal Thakkar, who is currently serving as chief medical officer and has been at the pharma group for more than two decades.

The company has named Dr. Roopal Thakkar as EVP of R&D and Chief Scientific Officer and is requesting FDA and EMA clearance ...

Roopal Thakkar, AbbVie’s chief scientific officer, says drugmakers are “getting better at cracking that code”, adding that improvements in brain imaging and the ability to combine different ...

GlobalData is the parent company of Pharmaceutical Technology. In the announcement accompanying the approval, AbbVie’s chief medical officer Roopal Thakkar said: “The full FDA approval of ELAHERE for ...

The announcement comes shortly after AbbVie's head of global R&D Thomas Hudson retired, to be replaced by Roopal Thakkar, and after Pfizer chief scientific officer and president of R&D Mikael ...

"Patients with non-small cell lung cancer have unmet medical needs and oncologists are looking for new treatment options for these patients who unfortunately have a poor prognosis," said Roopal ...

AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

This positive opinion recognizes the unmet need for certain patients with platinum-resistant ovarian cancer," said Roopal Thakkar, M.D., executive vice president, research and development ...

AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...

North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...

While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among patients under 50 .